L
Lisa A. Kachnic
Researcher at Columbia University
Publications - 278
Citations - 11131
Lisa A. Kachnic is an academic researcher from Columbia University. The author has contributed to research in topics: Radiation therapy & Cancer. The author has an hindex of 48, co-authored 251 publications receiving 9255 citations. Previous affiliations of Lisa A. Kachnic include Dresden University of Technology & Emory University.
Papers
More filters
Journal ArticleDOI
Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial
Vinai Gondi,Stephanie L. Pugh,Wolfgang A. Tomé,Chip Caine,Ben W Corn,Andrew A. Kanner,Howard A. Rowley,Vijayananda Kundapur,Albert S. DeNittis,Jeffrey Greenspoon,Andre Konski,Glenn Bauman,Sunjay Shah,Wenyin Shi,Merideth M Wendland,Lisa A. Kachnic,Minesh P. Mehta +16 more
TL;DR: Conformal avoidance of the hippocampus during WBRT is associated with preservation of memory and QOL as compared with historical series.
Journal ArticleDOI
Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline.
Stephen Lutz,Lawrence Berk,Eric L. Chang,Edward Chow,Carol A. Hahn,Peter Hoskin,David R. Howell,Andre Konski,Lisa A. Kachnic,Simon S. Lo,Arjun Sahgal,Larry N. Silverman,Charles von Gunten,Ehud Mendel,Andrew D. Vassil,Deborah Watkins Bruner,William F. Hartsell +16 more
TL;DR: Radiotherapy is a successful and time efficient method by which to palliate pain and/or prevent the morbidity of bone metastases and is recommended for surgical decompression and postoperative radiotherapy in highly selected patients with sufficient performance status and life expectancy.
Journal ArticleDOI
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Lisa A. Kachnic,Kathryn Winter,Robert J. Myerson,Michael Goodyear,John Willins,Jacqueline Esthappan,Michael G. Haddock,Marvin Rotman,Parag J. Parikh,Howard Safran,Christopher G. Willett +10 more
TL;DR: Although the primary endpoint was not met, DP-IMRT was associated with significant sparing of acute grade 2+ hematologic and grade 3+ dermatologic and gastrointestinal toxicity, which emphasizes the importance of real-time radiation quality assurance for IMRT trials.
Journal ArticleDOI
Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: A Radiation Therapy Oncology Group Consensus Panel Contouring Atlas
Robert J. Myerson,Michael C. Garofalo,Issam El Naqa,Ross A. Abrams,Aditya Apte,Walter R. Bosch,Prajnan Das,Leonard L. Gunderson,Theodore S. Hong,J.J. John Kim,Christopher G. Willett,Lisa A. Kachnic +11 more
TL;DR: This report serves as a template for the definition of the elective CTVs to be used in IMRT planning for anal and rectal cancers, as part of prospective RTOG trials.
Journal ArticleDOI
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Paul D. Brown,Vinai Gondi,Stephanie L. Pugh,Wolfgang A. Tomé,Jeffrey S. Wefel,Terri Armstrong,Joseph Bovi,Cliff G. Robinson,Andre Konski,Deepak Khuntia,David R. Grosshans,Tammie L.S. Benzinger,Deborah Watkins Bruner,Mark R. Gilbert,David Roberge,Vijayananda Kundapur,Kiran Devisetty,Sunjay Shah,Kenneth Y. Usuki,Bethany Anderson,Baldassarre Stea,Harold Yoon,Jing Li,Nadia N. Laack,Tim J. Kruser,Steven J. Chmura,Wenyin Shi,Snehal Deshmukh,Minesh P. Mehta,Lisa A. Kachnic +29 more
TL;DR: HA-WBRT plus memantine better preserves cognitive function and patient-reported symptoms, with no difference in intracranial PFS and OS, and should be considered a standard of care for patients with good performance status who plan to receive WBRT for brain metastases with no metastases in the HA region.